Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 1
Submit an article Journal homepage
58
Views
16
CrossRef citations to date
0
Altmetric
Review

Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck

Barbara A Murphy Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232-6307, USA. [email protected]
Pages 85-92 | Published online: 22 Apr 2005

Bibliography

  • Cancer Facts and Figures 2000. American Cancer Society, Atlanta GA, USA (2000).
  • FORASTIERE A. KOCH W, TROTTI A, SIDRANSKY D: Medical Progress: head and neck cancer. N Engl. J. Med. (2001) 345:1890–1900.
  • LAMONT EB, VOKES EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol (2001) 2:261–269.
  • •A good review of the role of chemotherapy in the treatment of HNC with an emphasis on combined modality therapy.
  • GILBERT J, FORASTIERE AA: Organ preservation trials for laryngeal cancer. Otolaryngol Clin. North Am. (2002) 35:1035–1054.
  • •This review focuses on the use of combined modality therapy for the treatment of patients who desire function preservation with a radiation-based treatment approach.
  • SNIEZEK JC: Local treatment modalities for recurrent cancer of the head and neck. In: Atlas of Cancer. M Markman (Ed.), Lippincott Williams and Wilkins (2003):28–31.
  • DAVIDSON J, KEANE T, BROWN D et al.: Surgical salvage of oral and oraopharyngeal cancer recurring after radical radiotherapy. Arch. Otolaryngol Head Neck Surg. (1997) 123:420–424.
  • PACHECO-OJEDA L, MARANDAS P, JULIERON M et al: Salvage surgery by composite resection for epidermoid carcinoma of the tonsillar region. Arch. Otolaryngol Head Neck Surg. (1992) 118:181–184.
  • STEVENS KR, BRITSCH A, MOSS WT:High-dose reirradiation of the head and neck cancer with curative intent. Int. J. Radiation Oncol Biol. Phys. (1994) 29:687–698.
  • •A good review of the older literature on re-irradiation.
  • KAO J, GAROFALO ML, MILANO MT et al: Re-irradiation of recurrent and primary head and neck malignancies. Cancer Treat. Rev. (2003) 29:21–30.
  • ••An excellent contemporary review ofre-irradiation.
  • SPENCER SA, HARRIS J, WHEELER PHet al: RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-flurouracil in patients with head and neck cancer. Int. J. Radiat. Oncol Biol. Phys. (2001) 51:1299–3004.
  • •This is the most recently published Cooperative Oncology Group experience with this cohort of patients.
  • COOPER JS, PAJAK T, FORASTIERE AA et al.: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl. J. Med. (2004) 350:1937–1941.
  • BERNIER J, BOMERGE C, OZSAHIN M et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl. J. Med. (2004) 350:1798–1804.
  • PACAGNELLA A, ORLANDO k MARCHIORI C et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the gruppo di studio sui Tumori della Testa e del Collo. J. Natl. Cancer Inst. (1994) 86:265–272.
  • MURPHY BA: Metastatic and recurrent head and neck cancer: treatment and outcomes. In: Atlas of Cancer. M Markman (Ed.), Lippincott Williams and Wilkins (2003):36.
  • TRIGO J, HITT R, KORALEWSKI P et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCHHN): results of a Phase II study. Proc. Am. Soc. Clin. Oncol (2004) 23:5580.
  • COHEN EE, ROSEN F, STADLER -WM et al.: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol (2003) 21:1980–1987.
  • FORASTIERE AA, LEONG T, ROWINSY E et al.: Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Group Study E1393. J. Clin. Oncol (2001) 19:1088–1095.
  • MURPHY BA, LI Y, CELLA D et al.: Phase III study comparing cisplatin and 5-flurouracil versus cisplatin and paclitaxel in metastatic/recurrent head and neck cancer. Proc. Am. Soc. Clin. Oncol (2001) (Abstract 894).
  • WANG JC: DNA Topoisomerases. Annu. Rev. Biochem. (1996) 65:635–692.
  • •Although this review is from 1996, the author provides an in-depth summary of DNA topoisomerase biology and function.
  • GUPTA M, FUJIMORI A, POMMIER Y: Eucaryotic DNA topoisomerases I. Biochim. Biophys. Acta (1995) 1262:1–14.
  • ••An excellent, but brief, review of thebiological functions of topoisomerase I enzymes and inhibitors.
  • POURQUIRE P, PILON AA, KOHLHAGEN G, MAZUMDER A, SHARMA A. POMMIER Y: Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. J. Bio. Chem. (1997) 272:26441–26447.
  • ROTHENBERG M: Topoismerase I inhibitors: review and update. Ann. Oncol (1997) 8:837–855.
  • ••An excellent review of topoisomerase Iinhibitors in clinical trials.
  • ARGIRIS A. MURREN JR: Clinical use of the camptothecins at year 2000. PPO Updates (2000) 14:1–15.
  • ••An excellent review of topoismerase Iinhibitors in clinical trials.
  • ROBERT F, SOONG S, WHEELER RH: A Phase II study of topotecan in patients with recurrent head and neck cancer. Am. J. Clin. Oncol (1997) 20:298–302.
  • SMITH RE, LEWD, RODRIGUEZ GI et al.: Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest. New Drugs (1996) 14:403–407.
  • MURPHY BA, LEONG T, BURKEY B, LANGER C, FORASTIERE A: Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Am. J. Clin. Oncol (2001) 24:64–66.
  • HADDAD RI, VAN ECHO DA: Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer. Cancer Chemother. Pharmacol (2003) 52:303–306.
  • MURPHY BA, CMELAK A. BURKEY B et al.: Topoisomerase I inhibitors in the treatment of head and neck cancer. Oncology (2001) 15:48–52.
  • KANO Y, SUZUKI K, AKUTSU M et Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer. (1992) 50:604–610.
  • KUDOH S, TAKADA S, MASUDA N et aL: Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of
  • •• camptothecin, and cisplatin against human lung tumor xenographs.Jpn. J. Cancer Res. (1993) 84:203–207.
  • JAGASIA MH, LANGER CJ, JOHNSON DH et al.: Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter Phase II study. Clin. Cancer Res. (2001) 7:68–73.
  • IKPEAZU CV, MURPHY BA, KISH B et al.: Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck (RMHNC). Proc. Am. Soc. Clin. Oncol (2004) 23:5580.
  • FORASTEIERE AA, URBA SG: Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin. Oncol (1995) 22:24–27.
  • KANO Y, AKUTSU M, TSUNODA S et al.: In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother. Pharmacol (1998) 42:91–98.
  • MURREN J, BLUM K, GALLIPOLI MA, RICH R: Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule. Oncology (2001) 51:25–30.
  • LAD T, ROSEN B, BROCKSTEIN R et al: Phase II trial of 9-aminocamptothecin (9AC/DMA) in patients with advanced squamous cell head and neck cancer. Proc. Am. Soc. Clin. Oncol (1998) 17:392a.
  • LAMOND JP, WANG M, KINESELLATJ, BOOTHMAN DA: Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors. Int. J. Radix-. Oncol Biol. Phys. (1996) 36:369–376.
  • ••In addition to presenting their data onradiation enhancement with 9-AC, the authors review early predinical literature on the radiation sensitising properties of topoisomerase I agents.
  • CHEN AY, OKUNIEFF P, POMMIER Y, MITCHELL JB: Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res. (1997) 57:529–536.
  • MIYAMATO S, HUANG TT, WUERZBERGER-DAVIS S et al: Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann. IVY Acad. Sci. (2000) 922:274–292.
  • LAMOND JP, WANG M, KINESELLA TJ, BOOTHMAN DA: Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int. J. Radiat. Oncol Biol. Phys. (1996) 36:361–368.
  • TAMURA K, TAKDA M, KAWASW I et al: Enhancement of tumor raido-response by irinotecan in human lung tumor xenographs.Jpn. J. Cancer Res. (1997) 88:218–223.
  • BOOTHMAN DA, FUKUNAGA N, WANG M: Down-regualtion of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res. (1994) 54:4618–4626.
  • BOOTHMAN DA, PARDEE AB: Inhabition of radiation-induced neoplastic transformation by b-lapachone. Proc. Nail Acad. Sci. (1989) 86:4963–4967.
  • BOOTHMAN DA, TRASK DK, PARDEE AB: Anticarcinogenic potential of DNA repair in human tumor cells by B-lapachone, an activator of topoisomerase I. Cancer Res. (1989) 49:605–612.
  • CHASTAGNER P, MERLIN JL, MARCHAL C et al: In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice. Clin. Cancer Res. (2000) 6:3327–3333.
  • MATTERN MR, HOFMANN FL, MCCABE FL, JOHNSON RK: Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan. Cancer Res. (1991) 51:5813–5816.
  • CHOY H, MACRAE R: Irinotecan and radiation in combined-modality therapy for solid tumors. Oncology (2001) 15:22-28. The authors provide an excellent review of irinotecan as a radiation-sensitising agent for solid tumor malignancies. The review addresses irinotecan activity, radiosensitisation and an extensive review of clinical trials.
  • ILSON DH, BAINS M, KELSON D et al.:Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J. Clin. Oncol (2003) 21:2926–2932.
  • FISHER B, SCOTT C, MACDONALD DR, CURRAN WJ: Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of radiation therapy Oncology Group Trial 9507.1 Clin. Oncol (2001) 19:1111–1117.
  • SALAMA JK, HARAF DJ, STENSON K, VOKES E: Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU and hydroxyurea for patients with advanced and/or recurrent head and neck cancer: toxicity and outcome results. Proc. Amer. Soc. Clin. Oncol (2004) 23:5561.
  • KOUKOURAKIS MI, BIZAKIS JG, SKOULAKIS CE et al: Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer: a Phase I dose escalation study. Anticancer Res. (1999) 19:2305–2309.

Website

  • http://www. ECOG.org Eastern Cooperative Oncology Group website.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.